In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exubera's Problem: It's Still Just Insulin

Executive Summary

Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.

You may also be interested in...



Oral Molecules In An Injectable World: What Developers Need To Do Now

Companies developing new orally delivered molecules for specialty markets must position their drugs as more than just convenient alternatives to injectable therapies.

Oral Molecules In An Injectable World: What Developers Need To Do Now

Companies developing new orally delivered molecules for specialty markets must position their drugs as more than just convenient alternatives to injectable therapies.

Blow the Launch -- Doom the Product

A new IMS survey shows that payors are now virtually the most important determinant of marketplace success -- far more important, in most markets, including the US, than sales representatives, who are less influential than they have ever been. Moreover, marketers who can't create a strong market penetration within six months of launch, will almost certainly fail - no matter what they do - to be able to improve the sales curve.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel